Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome with Positive Interim Data and Registrational Trial Progress
Key Insights
Neurogene reported positive interim data from its Phase 1/2 trial of NGN-401, showing all eight pediatric participants gained developmental milestones across core domains of Rett syndrome (search) with durable improvements lasting up to 24 months.
The company has dosed multiple participants in its Embolden registrational trial in Q4 2025 and expects to complete dosing in Q2 2026, with interim data from both pediatric and adolescent/adult cohorts planned for mid-2026.
NGN-401 at the 1E15 vg dose continues to demonstrate a favorable safety profile with no evidence of hemophagocytic lymphohistiocytosis (search) (HLH (search)), positioning the therapy as a potential best-in-class treatment for Rett syndrome (search).
Neurogene Inc. has reported encouraging progress for its investigational gene therapy NGN-401 in treating Rett syndrome (search), with positive interim clinical data from its Phase 1/2 trial and advancement of its pivotal Embolden registrational study. The company dosed multiple participants in the registrational trial during the fourth quarter of 2025 and expects to complete dosing in the second quarter of 2026.
Strong Efficacy Signal Across Disease Spectrum
Updated interim data from the Phase 1/2 trial demonstrated that all eight pediatric participants (ages 4-10) experienced functional gains across the spectrum of disease severity. The participants collectively gained 35 developmental milestones and skills across core clinical domains of Rett syndrome (search), including hand function/fine motor skills, language/communication, and ambulation/gross motor function.
"All pediatric participants, regardless of baseline disease severity, have gained developmental milestones/skills or experienced functional gains, with durability and continued skill acquisition over time," said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "These skill gains far exceed the bar for our Embolden registrational trial, and coupled with NGN-401's tolerability profile at the 1E15 vg dose, create the potential for a best-in-class gene therapy for Rett syndrome (search)."
The improvements have proven durable, with multidomain benefits observed up to 24 months post-treatment. Participants with longer-term follow-up continued to gain developmental milestones and skills, with notable gains in executive function and motor planning for those with the longest follow-up periods.
Favorable Safety Profile at Registrational Dose
NGN-401 at the 1E15 vg dose has been generally well-tolerated across both the pediatric cohort and the adolescent/adult cohort (ages ≥11). All treatment-related adverse events have been mild (Grade 1) or moderate (Grade 2) in severity, with the majority representing known potential risks of AAV therapy that have resolved or are resolving.
Importantly, no evidence of hemophagocytic lymphohistiocytosis (search) (HLH (search)) has been observed in any participant at the current dose level. The company had previously observed HLH at a higher 3E15 dose but expressed confidence in the safety profile at the current 1E15 dose, which is three times lower than the dose where HLH occurred.
Regulatory Strategy and Commercial Preparation
NGN-401 has received multiple regulatory designations, including selection for the FDA's START Pilot Program, Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation, and rare pediatric designation from the FDA. The therapy also received Priority Medicines (PRIME) designation from the European Medicines Agency (search).
According to Christine Mikail, President and CFO of Neurogene, the company maintains quarterly meetings with the FDA under its START designation, receiving written feedback on both clinical and CMC matters. The FDA has advised that a six-month interim analysis would not be sufficient for registration purposes, leading the company to plan for longer follow-up periods.
Unique Therapeutic Approach
NGN-401 represents the first clinical candidate to deliver the full-length human MECP2 (search) gene under the control of Neurogene's proprietary EXACT transgene regulation technology. This approach addresses a critical challenge in Rett syndrome (search) gene therapy, as MECP2 has a narrow therapeutic window and can be highly toxic when overexpressed.
The therapy utilizes intracerebroventricular (ICV) delivery to target key brain areas implicated in Rett syndrome (search). Based on market research, caregivers generally understand the disease's brain origin and have not viewed ICV delivery as a barrier, while payers have indicated they are largely "route agnostic" and focused on objective, disease-modifying efficacy.
Market Outlook and Competition
Mikail characterized Rett syndrome (search) as not a "winner-takes-all" market, suggesting multiple players could be supported. She noted that caregivers are thoughtful consumers because patients generally cannot be redosed with gene replacement therapy, and adoption is expected to take time rather than forming rapid uptake.
The company views Rett syndrome (search) as a centers-of-excellence market that is "finite and containable" to commercialize. The pivotal study utilizes 13 sites representing approximately 60% of U.S. Rett centers of excellence, which could convert into top-tier commercial sites.
Upcoming Milestones
Neurogene plans to present interim safety and efficacy data on both the pediatric cohort (ages 4-10; n=8) and the adolescent/adult cohort (ages ≥11; n=2) from the Phase 1/2 trial in mid-2026, including at least 12 months of follow-up for all participants. The company expects to complete dosing in the Embolden registrational trial in the second quarter of 2026.
With cash runway expected through the first quarter of 2028, Neurogene believes it is well-positioned to advance NGN-401 through key upcoming milestones, including a BLA submission, while continuing early commercial-readiness activities.